Risk Factors Update Summary
- Accumulated deficit increased from $348 million to $468 million, impacting financial stability.
- Risks related to development include potential delays in FDA approval and market acceptance.
- Net proceeds from various stock issuances decreased from $30 million to $12 million.
- Substantial doubt exists regarding funding adequacy beyond 2026, impacting long-term viability.
- Completion of private placement resulted in net proceeds of approximately $100 million.
- Ability to use net operating losses for tax benefits extended to tax years ending after December 31, 2017.
- Cash and cash equivalents increased from $30.6 million to $153.7 million.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1697532&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.